Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2005

View Archived Issues

Neuropeptide Y Y2 antagonist effective in rats with ethanol dependence

Neuroprotective effects of thiazolidinediones in a preclinical model of stroke

RP-101 reported to improve survival in patients with advanced pancreatic cancer

Phase II data on the benefits of PT-141 in female sexual dysfunction

Putative antidepressant LY-367265 inhibits glutamate release in rat cortex

Update on the efficacy of rasburicase in the prevention of hyperuricemia in cancer patients

Ondansetron improves auditory gating in schizophrenic patients

Positive findings in phase II study of ProMune plus chemotherapy in NSCLC

ReceptoPharm plans phase IIb/III study of RPI-78M in adrenomyeloneuropathy

Phase IIb/III DIAS2 study begins for desmoteplase in acute ischemic stroke

Boehringer Ingelheim discontinues development of bivatuzumab mertansine

Adderall XR sales suspended in Canada

Pharmacokinetic study of TRANSDUR-based sufentanil patch completes dosing

Phase II study of Durect's postoperative pain relief depot product progresses

Positive phase III results for Nuvigil

XP-13512 enters phase IIb study for restless legs syndrome

SPA agreement for phase III study of Cloretazine in relapsed AML

Vical completes SPA for Allovectin-7

SOT-107 receives Japanese orphan drug status

Three series of chemokine CCR4 receptor modulators claimed by AstraZeneca

New anticoagulant agents reported by Bristol-Myers Squibb

Aventis imparts new tubulin polymerization inhibitors for cancer therapy

Novel antiinflammatory chalcones patented by AtheroGenics

Bristol-Myers Squibb patent covers new antiinflammatory agents

Metabotropic glutamate (mGluR5) receptor antagonists described in patent literature

First anti-HIV dual CCR5/CXCR4 antagonist described / News in Context

New title added to the Drug R&D Backgrounders topic list - Osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...